Makoto Ishitobi

Modified abdominal advancement flap with or without the Ochikomanai method: Oncoplastic surgery using a simple volume replacement technique

Erina Hatakawa, Kaho Nakamura, Rena Yamakado, Miyuko Yoshikawa et autres

PURPOSE: To evaluate the usefulness of modified abdominal advancement flap (modified AAF) with and without the Ochikomanai method for breast-conserving surgery (BCS) based on cosmetic results and patient satisfaction. METHODS: We conducted a retrospective cohort study focusing on the usefulness of the …

jp (code pays fourni par la source)

Correction: Differences in drug efficacy and prognosis between primary and metastatic sites for de novo stage IV breast cancer: an exploratory analysis of a phase III trial, JCOG1017

Kiyo Tanaka, Akihiko Shimomura, Makoto Ishitobi, Takashi Yamanaka et autres

jp (code pays fourni par la source)

Primary tumour resection reduces the risk of major local morbidity in de novo stage IV breast cancer: secondary data analysis from the JCOG1017 randomized clinical trial

Makoto Ishitobi, Kiyo Tanaka, Akihiko Shimomura, Takashi Yamanaka et autres

Makoto Ishitobi, Kiyo Tanaka, Akihiko Shimomura, Takashi Yamanaka, Takahiro Tsukioki, Hiroji Iwata, Fumikata Hara, Tomomi Fujisawa, Keita Sasaki, Riku Kaji

ch, jp (code pays fourni par la source)

Differences in drug efficacy and prognosis between primary and metastatic sites for de novo stage IV breast cancer: an exploratory analysis of a phase III trial, JCOG1017

Kiyo Tanaka, Akihiko Shimomura, Makoto Ishitobi, Takashi Yamanaka et autres

BACKGROUND: Breast cancer is a highly heterogeneous disease, with biological factors like estrogen receptor, progesterone receptor, and HER2 receptor differing between primary and metastatic sites, potentially affecting treatment response. This exploratory analysis aims to differentiate drug efficacy and long-term prognosis between these …

jp (code pays fourni par la source)

Changes in re-excision rates after publication of guidelines defining positive margins for breast-conserving surgery: a collaborative study of the Japanese breast cancer society

Takehiko Sakai, Yuri Kimura, Makoto Ishitobi, A. Yoshida et autres

jp (code pays fourni par la source)

Abstract PS2-01-22: Changes in reoperation rate after publication of guidelines defined positive margins for breast conserving surgery: Collaboration study of Japanese Breast Cancer Society

T. Sakai, Makoto Ishitobi, Y. Sagara, A. Yoshida et autres

Abstract Background: In 2014, the SSO-ASTRO consensus guidelines redefined a positive margin requiring re-excision after breast-conserving surgery (BCS) as “tumor on ink.” The adoption of this standard has been reported internationally to significantly reduce the rate of surgical re-excision for positive margins. …

jp (code pays fourni par la source)

Efficacy and prognostic predictors of primary systemic therapy for de novo Stage IV breast cancer. Exploratory analysis of JCOG1017 PRIM-BC

Tadahiko Shien, Makoto Ishitobi, Keita Sasaki, Kiyo Tanaka et autres

The optimal initial systemic therapy for de novo Stage IV breast cancer (BC) is critical, particularly to assess early drug efficacy. In the JCOG1017 trial, untreated de novo Stage IV BC patients received 3 months of subtype-based systemic therapy before randomization for …

jp (code pays fourni par la source)

Efficacy and prognostic predictors of primary systemic therapy for de novo Stage IV breast cancer. Exploratory analysis of JCOG1017 PRIM-BC.

Tadahiko Shien, Makoto Ishitobi, Keita Sasaki, Kiyo Tanaka et autres

jp (code pays fourni par la source)

Development and Validation of an Ipsilateral Breast Tumor Recurrence Risk Estimation Tool Incorporating Real-World Data and Evidence From Meta-Analyses: A Retrospective Multicenter Cohort Study

Yasuaki Sagara, Atsushi Yoshida, Yuri Kimura, Makoto Ishitobi et autres

PURPOSE: Ipsilateral breast tumor recurrence (IBTR) remains a critical concern for patients undergoing breast-conserving surgery (BCS). Reliable risk estimation tools for IBTR risk can support personalized surgical and adjuvant treatment decisions, especially in the era of evolving systemic therapies. We aimed to …

jp (code pays fourni par la source)

A retrospective multi-center cohort study investigating safety of sentinel lymph node biopsy for axillary staging in clinical T3-4c breast cancer

Sayaka Kuba, Yasuaki Sagara, Hiroshi Yano, Shigeto Maeda et autres

jp (code pays fourni par la source)

Abstract P5-10-05: Differences in drug efficacy between primary and metastatic sites and their prognosis for de novo stage IV breast cancer: an exploratory analysis of a phase III trial, JCOG1017

Kiyo Tanaka, Akihiko Shimomura, Makoto Ishitobi, Takashi Yamanaka et autres

Abstract Background: Breast cancer is a highly heterogeneous disease, and there is a biological diversity. Biological factors such as estrogen receptor, progesterone receptor, and HER2 receptor may vary between primary and metastatic sites in breast cancer. This variation could influence treatment responses …

Impact of margin status on ipsilateral breast tumor recurrence after breast-conserving treatment for patients with breast cancer who received neoadjuvant chemotherapy: a retrospective multi-institutional study of 1813 cases

Makoto Ishitobi, Atsushi Yoshida, Yuri Kimura, Yasuaki Sagara et autres

jp (code pays fourni par la source)